Celgene Corporation company logo

# 1st Gen Model Celgene Corporation Pharmaceutical preparations

Subscribe >> Deal exit on
Dec. 18, 2017
68.97% successful of 87 deals
$109.41 Last close price
at 15-dec-2017


Model's trade recommendations 1.99% Return for period

9.87% Annual return

$85.19B Market Cap

β 1.78  


Model (following trade recommendations)


Underlying stock

S&P 500

Return for period 1.99%
52wk return -1.59%
52wk Range
Sortino ratio 1.03
Sharpe ratio 0.75
Norm. RMSE 0.48%
Downside risk 9.68%
Volatility 13.23%
  • STRONG BUY Analysts consensus recommendation

Celgene Corporation is a global integrated biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases in patients with limited treatment options. There are hundreds of clinical trials at major medical centers evaluating compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma (MM), myelodysplastic syndromes (MDS), chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), pancreatic cancer, non-small lung cancer and melanoma. In addition, several compounds are being evaluated as therapies for serious inflammatory diseases such as psoriasis and psoriatic arthritis. The company's major product is Revlimid (lenalidomide), in combination with dexamethasone for the treatment of multiple myeloma patients.

Industry sector: Medical

Sector classification: Pharmaceutical preparations

Deep Learning based analysis and prediction model for Celgene Corporation (CELG) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since Oct. 2, 2015.

Market data for CELG model training are being downloaded from the Quandl premium datasets on a daily basis.

Model is being retrained on a daily basis.

Float 780M
P/E 16.91
Shares Outstanding 787M
% Held by Insiders 0.95%
% Held by Institutions 80.16%
EPS (last reported FY) $5.18
EPS (last reported Q) $1.78
EPS, estimated (last reported Q) $1.72
Total revenues $11 B
Net income $2 B